PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab

Conclusions: PERCIST-derived metabolic volume response predicts survival in pretreated patients with malignant mesothelioma receiving high-dose pembrolizumab. These results warrant inclusion of PET response assessment in future clinical trials and routine practice.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Ferdinandus, J., Barbato, F., Chodyla, M., Fendler, W., Kessler, L., Metzenmacher, M., Krefting, F., Hager, T., Herrmann, K., Christoph, D. Tags: Lung Cancer I Source Type: research